TNGX — Tango Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1819133 ·
Last close
$24.51
Market Cap
$4.13B
52W High
$34.39
52W Low
$19.43
ADV30
2,223,687
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -48,769,000 | -45,514,000 | 435,792,000 | 157,828,000 | 44,286,000 |
| Dec 2025 | 0 | — | -41,864,000 | -38,749,000 | 398,690,000 | 112,279,000 | 52,511,000 |
| Sep 2025 | 53,811,000 | — | 14,072,000 | 15,884,000 | 210,136,000 | 58,338,000 | 50,105,000 |
| Jun 2025 | 3,181,000 | — | -40,967,000 | -38,853,000 | 237,890,000 | 39,272,000 | 102,936,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-141,549,000
Investing CF
$-61,827,000
Financing CF
$302,344,000
CapEx
$-1,048,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.83
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-648,666,000
Inventory
—
Receivables
—
ST Investments
$222,011,000
EBIT TTM
$-117,528,000
Pretax Income TTM
$-107,261,000
Interest Exp TTM
—
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$53,811,000
EBITDA
$-134,424,992
Free Cash Flow
$-71,874,872
Enterprise Value
$3,044,417,536
Total Cash
$1,013,990,016
Total Debt
$31,992,000
Shares Out
168,610,367
Trailing EPS
$-0.84
Book Value
$2.72
ROE
-21.3%
ROA
-13.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 62,384,000 | -111,289,000 | -101,594,000 | 398,690,000 | 52,511,000 | — | -138,886,000 |
| Dec 2024 | 42,069,000 | -145,595,000 | -130,302,000 | 316,492,000 | 116,975,000 | — | -131,501,000 |
| Dec 2023 | 36,527,000 | -114,173,000 | -101,744,000 | 402,567,000 | 149,459,000 | — | -117,982,000 |
| Dec 2022 | 24,860,000 | -111,071,000 | -108,176,000 | 436,470,000 | 186,994,000 | — | -109,080,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.63
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $25.00 · spot: $24.51 · call volume: 306 · put volume: 326
Expected Move to 2026-10-16:
±$5.65
(23.05%) —
implied range
$18.86 –
$30.16
· ATM straddle on $25.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MANE | Veradermics, Inc | $4.11B | $98.46 | — |
| LEGN | Legend Biotech Corp | $4.07B | $20.94 | — |
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.25B | $38.15 | — |
| INDV | Indivior Pharmaceuticals, Inc. | $4.27B | $36.18 | — |
| GIKLY | Grifols SA | $4.31B | $5.10 | — |
News headlines (Yahoo Finance, 1h cache)
Tango Therapeutics Announces Executive Chair Transition
2026-08-06 22:24 · Yahoo
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%
2026-07-22 13:55 · Yahoo
Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues
2026-07-15 14:01 · Yahoo
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
2026-07-02 14:50 · Yahoo
Tango Therapeutics Appoints Robert Azelby to Board of Directors
2026-06-22 20:05 · Yahoo
Is Tango Therapeutics (TNGX) Price Justified After Its 7x Surge In One Year
2026-06-10 08:10 · Yahoo
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
2026-08-12 14:46 · Yahoo
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
2026-08-11 11:00 · Yahoo
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer
2026-07-23 17:10 · Yahoo
2 Monster Growth Stocks Analysts Think Can Reach New Highs
2026-07-09 17:54 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.